Retargeted herpesvirus with a glycoprotein H fusion

Patent metadata

Field	Value
Publication number	US-10421979-B2
Application number	US-201615548731-A
Country	US
Kind code	B2
Filing date	Feb 11, 2016
Priority date	Feb 11, 2015
Publication date	Sep 24, 2019
Grant date	Sep 24, 2019

Abstract

The present invention relates to the field of disease therapy. More specifically, it relates to a retargeted herpesvirus having a heterologous polypeptide fused to glycoprotein H, wherein the polypeptide targets diseased cells. It also relates to a nucleic acid comprising the genome of the herpesvirus of the invention, a vector comprising this nucleic acid and a cell comprising the nucleic acid or the vector. It further relates to killing cells using the herpesvirus of the invention and to methods for growing it in vitro.

First claim

The invention claimed is:

1. A recombinant infectious herpesvirus comprising a heterologous polypeptide ligand inserted into mature glycoprotein H (gH)
(i) between amino acid 23 and amino acid 24 of the gH according to SEQ ID NO: 1 or a corresponding region of a homologous gH, or
(ii) within the region starting at amino acid 116 and ending at amino acid 136 of the gH according to SEQ ID NO: 1 or a corresponding region of a homologous gH.

2. The recombinant infectious herpesvirus of claim 1 , wherein one or more gH amino acids of the N-terminal region are deleted.

3. The recombinant infectious herpesvirus of claim 1 , wherein said herpesvirus has a reduced virulence compared to a wildtype, or has a higher replicative capacity in diseased cells than in non-diseased cells.

4. The recombinant infectious herpesvirus of claim 1 , comprising an altered glycoprotein D (gD) having reduced specific binding to gD's cellular ligands compared to wildtype gD or having no specific binding to gD's cellular ligands, or which lacks gD.

5. A recombinant infectious herpesvirus comprising a heterologous polypeptide ligand fused to the N-terminus of mature glycoprotein H (gH) or of a truncated gH, or inserted into gH, and further comprising a heterologous polypeptide ligand fused to the N-terminus of mature gD or of a truncated gD, or inserted into gD.

6. The recombinant infectious herpesvirus of claim 1 , further comprising a heterologous detectable marker and/or one or more expression cassettes expressing one or more of the following
i) one or more therapeutic proteins,
ii) one or more heterologous or autologous antigens, epitopes/neoepitopes or string of epitopes/neoeptitopes, or
iii) one or more prodrug-converting enzymes.

7. The recombinant infectious herpesvirus of claim 1 , wherein the heterologous polypeptide ligand fused to or inserted into gH binds to a molecule or part thereof accessible on the surface of a cell.

8. The recombinant infectious herpesvirus of claim 1 for use in medicine.

9. The recombinant infectious herpesvirus of claim 4 , comprising an altered glycoprotein D (gD), wherein gD has an amino acid deletion starting at any of amino acid residues 26 to 33 and ending at any of amino acid residues 31 to 63, and/or starting at any of amino acid residues 65 to 86 and ending at any of amino acid residues 235 to 243 of the gD according to SEQ ID NO: 4 or a corresponding region of a homologous gD.

10. The recombinant infectious herpesvirus of claim 7 , wherein the cell is a diseased cell.

11. The recombinant infectious herpesvirus of claim 5 , wherein the heterologous polypeptide ligand is inserted within the N-terminal region starting at any one of amino acids 19 to 23 and ending at any one of amino acids 48 to 88 or starting at amino acid 116 and ending at amino acid 136 of the gH according to SEQ ID NO: 1 or a corresponding region of a homologous gH.

12. The recombinant infectious herpesvirus of claim 5 , wherein the heterologous polypeptide ligand is inserted N-terminally of the H1A domain of gH.

13. The recombinant infectious herpesvirus of claim 5 , comprising an altered glycoprotein D (gD) having reduced specific binding to gD's cellular ligands compared to wildtype gD or having no specific binding to gD's cellular ligands, or which lacks gD.

14. The recombinant infectious herpesvirus of claim 5 , comprising an altered glycoprotein D (gD), wherein gD has an amino acid deletion starting at any of amino acid residues 26 to 33 and ending at any of amino acid residues 31 to 63, and/or starting at any of amino acid residues 65 to 86 and ending at any of amino acid residues 235 to 243 of the gD according to SEQ ID NO: 4 or a corresponding region of a homologous gD.

15. The recombinant infectious herpesvirus of claim 5 , wherein one or more gH amino acids of the N-terminal region are deleted.

16. The recombinant infectious herpesvirus of claim 5 , wherein said herpesvirus has a reduced virulence compared to the wildtype, or has a higher replicative capacity in diseased cells than in non-diseased cells.

17. The recombinant infectious herpesvirus of claim 5 , further comprising a heterologous detectable marker and/or one or more expression cassettes expressing one or more of the following:
i) one or more therapeutic proteins;
ii) one or more heterologous or autologous antigens, epitopes/neoepitopes or string of epitopes/neoeptitopes; or
iii) one or more prodrug-converting enzymes.

18. The recombinant infectious herpesvirus of claim 5 , wherein the heterologous polypeptide ligand fused to or inserted into gH and/or gD binds to a molecule or part thereof accessible on the surface of a cell.

19. The recombinant infectious herpesvirus of claim 18 , wherein the cell is a diseased cell.

20. The recombinant infectious herpesvirus of claim 5 for use in medicine.

21. A recombinant infectious herpesvirus comprising a heterologous polypeptide ligand fused to the N-terminus of mature glycoprotein H (gH) or of a truncated gH, or inserted into gH, and further comprising an altered glycoprotein D (gD), wherein gD has an amino acid deletion starting at any of amino acid residues 26 to 33 and ending at any of amino acid residues 31 to 63, and/or starting at any of amino acid residues 65 to 86 and ending at any of amino acid residues 235 to 243 of the gD according to SEQ ID NO: 4 or a corresponding region of a homologous gD.

22. The recombinant infectious herpesvirus of claim 21 , wherein the heterologous polypeptide ligand is inserted within the N-terminal region starting at any one of amino acids 19 to 23 and ending at any one of amino acids 48 to 88 or starting at amino acid 116 and ending at amino acid 136 of the gH according to SEQ ID NO: 1 or a corresponding region of a homologous gH.

23. The recombinant infectious herpesvirus of claim 21 , wherein the heterologous polypeptide ligand is inserted N-terminally of the H1A domain of gH.

24. The recombinant infectious herpesvirus of claim 21 , wherein one or more gH amino acids of the N-terminal region are deleted.

25. The recombinant infectious herpesvirus of claim 21 , wherein said herpesvirus has a reduced virulence compared to the wildtype, or has a higher replicative capacity in diseased cells than in non-diseased cells.

26. The recombinant infectious herpesvirus of claim 21 , comprising a heterologous polypeptide ligand fused to the N-terminus of mature gD or of a truncated gD, or inserted into gD.

27. The recombinant infectious herpesvirus of claim 21 , further comprising a heterologous detectable marker and/or one or more expression cassettes expressing one or more of the following:
i) one or more therapeutic proteins;
ii) one or more heterologous or autologous antigens, epitopes/neoepitopes or string of epitopes/neoeptitopes; or
iii) one or more prodrug-converting enzymes.

28. The recombinant infectious herpesvirus of claim 21 , wherein the heterologous polypeptide ligand fused to or inserted into gH and/or gD binds to a molecule or part thereof accessible on the surface of a cell.

29. The recombinant infectious herpesvirus of claim 28 , wherein the cell is a diseased cell.

30. The recombinant infectious herpesvirus of claim 21 for use in medicine.

Assignees

• Alma Mater Studiorum Univ Bologna
• Univ Bologna Alma Mater Studiorum

Inventors

• Campadelli Maria Gabriella
• Gatta Valentina

Classifications

• A61P31/22

  for herpes viruses · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N15/86

  Viral vectors · CPC title

• C12N15/62

  DNA sequences coding for fusion proteins · CPC title

• C12N2710/16632

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title